In contrast, blocking TNF-α (using etanercept or golimumab) in newly diagnosed T1D patients was associated with a slowed loss of C-peptide, suggesting a potential role for this pathway in T1D [60]. Here, TNF is linked to type 1 diabetes mellitus.